C4 Therapeutics, Inc. (CCCC)

6,45 -0,34 (-5,01%) Al cierre: 04:00PM EDT

C4 Therapeutics, Inc.

490 Arsenal Way
Suite120
Watertown, MA 02472
United States
617 231 0700
https://www.c4therapeutics.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 145

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Andrew J. Hirsch M.B.A.	CEO, President & Director	986,08k	N/A	1971
Dr. Kenneth C. Anderson M.D., Ph.D.	Co-Founder, Independent Director & Member of Scientific Advisory Board	45k	N/A	1951
Dr. Stewart Fisher Ph.D.	Chief Scientific Officer	674,57k	N/A	1967
Dr. Leonard M. J. Reyno M.D.	Chief Medical Officer	1,04M	N/A	1962
Dr. Nathanael S. Gray Ph.D.	Co-Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Ms. Kendra Adams	CFO & Treasurer	N/A	N/A	N/A
Mr. Mark Mossler	Chief Accounting Officer	N/A	N/A	1973
Ms. Jolie M. Siegel J.D.	Chief Legal Officer & Corporate Secretary	610,4k	1,06M	1977
Ms. Kelly A. Schick	Chief People Officer	N/A	N/A	1980
Dr. Isabel Chiu Ph.D.	Senior Vice President of Strategic Alliances & Business Development	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de C4 Therapeutics, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 3; Tablero: 7; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.